Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal irinotecan + vincristine + temozolomide + anlotinib
- Development stage
- Unknown
- Lead developer
- Tianjin Medical University Cancer Institute and Hospital
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination regimen, often referred to as IVT-A when including anlotinib, is being investigated by the Tianjin Medical University Cancer Institute and Hospital for the treatment of pediatric and adolescent patients with relapsed or refractory malignant solid tumors. The regimen combines the cytotoxic effects of liposomal irinotecan (a topoisomerase I inhibitor), vincristine (a microtubule-disrupting agent), and temozolomide (an oral alkylating agent) with the anti-angiogenic and multi-kinase inhibitory properties of anlotinib. Liposomal irinotecan provides a sustained-release formulation of the active metabolite SN-38, which inhibits DNA topoisomerase I, potentially increasing efficacy and reducing toxicity compared to standard irinotecan. Anlotinib targets VEGFR, FGFR, PDGFR, and c-Kit to inhibit tumor angiogenesis and proliferation. This multi-modal approach aims to overcome resistance in aggressive childhood cancers such as neuroblastoma and rhabdomyosarcoma.
- Other names
- IVT+A regimenIVT regimenliposomal irinotecan-Tianjin Medical University Cancer Institute and Hospital-malignant solid tumorLiposomal irinotecan-vincristine-temozolomide-anlotinib
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)TUBB (Tubulin (alpha and beta subunits))TOP1 (DNA Topoisomerase I)DNAPDGFRA (Platelet-derived growth factor receptor alpha)KIT (c-KIT proto-oncogene receptor tyrosine kinase)FGFR (FGFR family)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on liposomal irinotecan + vincristine + temozolomide + anlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal irinotecan + vincristine + temozolomide + anlotinib.